Opinioin: were masks really not necessary?
I have seen several other opinions about the mandatory masks during the pandemic of COVID-19, which is still officially not…
Pharmaceuticals, Biotechnology and Life Sciences
I have seen several other opinions about the mandatory masks during the pandemic of COVID-19, which is still officially not…
Actinium highlighted high rates of Complete Remission (CR/CRi) and rates of measurable residual disease (MRD) negativity with improved overall survival…
Moderna said Monday that both of its bivalent Omicron-targeting booster candidates (mRNA-1273.214 and mRNA-1273.222) trigger a superior antibody response compared…
In recent years, there has been an industry-wide recognition of the need for speed and agility. Accelerating the trial processes for COVID-19 vaccine candidates required proactive and cooperative efforts from participants at all points in the supply chain. A sense of urgency and an expectation that trials should be completed more quickly and effectively emerged as a result of the realization that a drug can be approved and released to the market in a relatively short period of time. In light of this, improving the speed, accuracy, and agility of clinical trials labeling — and more specifically, the translation of label content — is one of the crucial areas that would help organizations to achieve this.
Merck has exercised its option to jointly develop and commercialize personalized cancer vaccine (PCV) mRNA-4157/V940 pursuant to the terms of its existing Collaboration and License Agreement.
Inceptua Early Access, a business unit of the Inceptua Group, said it has teamed up with Sentynl Therapeutics Inc., a U.S.-based biopharmaceutical company, to make Sentynl’s Nulibry available via an Early Access Program for eligible patients with molybdenum cofactor deficiency (MoCD) Type A.
Dupixent presented detailed data at this year’s UEG Week conference in Vienna from from an investigational Phase 3 trial showing positive results in children ages 1 to 11 years old who are living with eosinophilic esophagitis (EoE). EoE is a chronic, progressive inflammatory disease that damages the esophagus and prevents it from working properly. Of the approximately 21,000 children under the age of 12 in the U.S. currently being treated for EoE, approximately 9,000 are most in need of new treatment options.
Vetter, a globally leading contract development and manufacturing organization (CDMO) with long-term experience in supporting biotechnology and pharmaceutical customers, has in place a comprehensive sustainability strategy that has made it a pioneer in this energy-intensive industry.
Enzyme biocatalysts can reduce costly synthesis and purification steps, thereby decreasing production costs. Through this collaboration, we aim to optimize…
4D pharma will not report its interim results for the 6 months to 30 June 2022 by 30 September as…